Luxturna wins unanimous backing from FDA advisers
Roche’s Erivedge is latest cancer drug to fall foul of NICE number-crunching.
Luxturna could be single life-changing injection
Merck & Co has said it will not file anacetrapib with regulators
New software open to developers to create innovative tools for predicting asthma conditions.
Medibio’s technology will be used to gather mental health biomarkers related to Otsuka’s Abilify.